Literature DB >> 24197986

KIAA0101 mRNA overexpression in peripheral blood mononuclear cells acts as predictive marker for hepatic cancer.

Xiaomei Su1, Tao Zhang, Peng Cheng, Yajie Zhu, Hua Li, Dong Li, Zhen Liu, Hui Gao, Zhenguo Zhao, Yu Zhao, Huanyi Liu.   

Abstract

KIAA0101 always overexpresses in tumor tissues, which is also a marker of tumor recurrence. This study aims to explore whether overexpression of KIAA0101 mRNA in peripheral blood mononuclear cells (PBMCs) could act as a noninvasive and predictive biomarker of hepatic cancer. Real-time polymerase chain reaction (RT-PCR) was employed to detect KIAA0101 mRNA expression in PBMCs isolated from 93 hepatic cancer patients and 55 healthy individuals. The diagnostic sensitivity and specificity of KIAA0101 mRNA, CEA, and CD44V were analyzed and compared. A multivariate logistic regression analysis was utilized to analyze risk factors for overall survival of hepatic cancer patients. A concordance analysis was employed to compare the overexpression of KIAA0101 mRNA with clinicopathological diagnosis. All of the 93 hepatic cancer patients were followed up routinely at least 36 months or until death to analyze the 3-year overall survival rate. The results indicated that KIAA0101 mRNA expression was increased significantly in hepatic patients' PBMCs, when compared with that of healthy individuals (P < 0.05). Both the sensitivity and specificity of KIAA0101 mRNA in PBMCs were enhanced significantly compared with those of the CEA and CD44V biomarkers. The multivariate logistic regression analysis indicated that the KIAA0101 mRNA level and pTNM stage were significantly related with the overall survival of the hepatic patients. There was a better concordance between KIAA0101 mRNA overexpression and clinicopathological diagnosis for hepatic cancer (kappa = 0.914, P < 0.001). KIAA0101 mRNA overexpression in PBMCs decreased the 3-year survival rate significantly. In conclusion, overexpression of KIAA0101 mRNA in PBMCs could act as a predictive biomarker for hepatic cancer and has a better sensitivity and specificity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24197986     DOI: 10.1007/s13277-013-1353-3

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  17 in total

1.  Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy.

Authors:  Nikolaus Kohles; Dorothea Nagel; Dietrich Jüngst; Jürgen Durner; Petra Stieber; Stefan Holdenrieder
Journal:  Tumour Biol       Date:  2011-09-20

2.  Identification of novel molecular markers for detection of gastric cancer cells in the peripheral blood circulation using genome-wide microarray analysis.

Authors:  Nobuyuki Matsumura; Hitoshi Zembutsu; Koji Yamaguchi; Kazuaki Sasaki; Tetsuhiro Tsuruma; Toshihiko Nishidate; Ryuichi Denno; Koichi Hirata
Journal:  Exp Ther Med       Date:  2011-04-08       Impact factor: 2.447

3.  KIAA0101 interacts with BRCA1 and regulates centrosome number.

Authors:  Zeina Kais; Sanford H Barsky; Haritha Mathsyaraja; Alicia Zha; Derek J R Ransburgh; Gang He; Robert T Pilarski; Charles L Shapiro; Kun Huang; Jeffrey D Parvin
Journal:  Mol Cancer Res       Date:  2011-06-14       Impact factor: 5.852

4.  The PCNA-associated factor KIAA0101/p15(PAF) binds the potential tumor suppressor product p33ING1b.

Authors:  Fiona Simpson; Kelly Lammerts van Bueren; Natalie Butterfield; Jennifer S Bennetts; Josephine Bowles; Christelle Adolphe; Lisa A Simms; Joanne Young; Michael D Walsh; Barbara Leggett; Lindsay F Fowles; Carol Wicking
Journal:  Exp Cell Res       Date:  2005-11-08       Impact factor: 3.905

5.  Serum carbohydrate antigen 19-9 as an indicator of liver metastasis in colorectal carcinoma cases.

Authors:  Hang Dong; Jie Tang; Long-Hao Li; Jun Ge; Xin Chen; Jing Ding; Hai-Tao Men; Wu-Xia Luo; Yang Du; Cong Li; Feng Zhao; Ye Chen; Ke Cheng; Ji-Yan Liu
Journal:  Asian Pac J Cancer Prev       Date:  2013

6.  Overexpression of KIAA0101 predicts poor prognosis in primary lung cancer patients.

Authors:  Tatsuya Kato; Yataro Daigo; Masato Aragaki; Keidai Ishikawa; Masaaki Sato; Mitsuhito Kaji
Journal:  Lung Cancer       Date:  2012-01       Impact factor: 5.705

7.  Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma.

Authors:  Ray-Hwang Yuan; Yung-Ming Jeng; Hung-Wei Pan; Fu-Chang Hu; Po-Lin Lai; Po-Huang Lee; Hey-Chi Hsu
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

8.  Suppression subtractive hybridization and expression profiling identifies a unique set of genes overexpressed in non-small-cell lung cancer.

Authors:  Joseph Petroziello; Andrew Yamane; Lori Westendorf; Melissa Thompson; Charlotte McDonagh; Charles Cerveny; Che-Leung Law; Alan Wahl; Paul Carter
Journal:  Oncogene       Date:  2004-10-07       Impact factor: 9.867

9.  Oncogenic role of KIAA0101 interacting with proliferating cell nuclear antigen in pancreatic cancer.

Authors:  Masayo Hosokawa; Akio Takehara; Koichi Matsuda; Hidetoshi Eguchi; Hiroaki Ohigashi; Osamu Ishikawa; Yasuhisa Shinomura; Kohzoh Imai; Yusuke Nakamura; Hidewaki Nakagawa
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

10.  Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53 activation.

Authors:  Lijuan Liu; Xiaobei Chen; Shuixiang Xie; Chuanjie Zhang; Zhenpeng Qiu; Fan Zhu
Journal:  Hepatology       Date:  2012-10-14       Impact factor: 17.425

View more
  7 in total

1.  A network-pathway based module identification for predicting the prognosis of ovarian cancer patients.

Authors:  Xin Wang; Shan-Shan Wang; Lin Zhou; Li Yu; Lan-Mei Zhang
Journal:  J Ovarian Res       Date:  2016-11-02       Impact factor: 4.234

2.  Variant 2 of KIAA0101, antagonizing its oncogenic variant 1, might be a potential therapeutic strategy in hepatocellular carcinoma.

Authors:  Lijuan Liu; Youyi Liu; Xiaobei Chen; Miao Wang; Yan Zhou; Ping Zhou; Wenxin Li; Fan Zhu
Journal:  Oncotarget       Date:  2017-07-04

3.  Low expression of PIK3C2A gene: A potential biomarker to predict the risk of acute myocardial infarction.

Authors:  Buchuan Tan; Miao Liu; Yushuang Yang; Long Liu; Fanbo Meng
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

4.  Common Molecular Alterations in Canine Oligodendroglioma and Human Malignant Gliomas and Potential Novel Therapeutic Targets.

Authors:  Dana Mitchell; Sreenivasulu Chintala; Kaleigh Fetcko; Mario Henriquez; Brij N Tewari; Atique Ahmed; R Timothy Bentley; Mahua Dey
Journal:  Front Oncol       Date:  2019-08-14       Impact factor: 6.244

5.  Kiaa0101 serves as a prognostic marker and promotes invasion by regulating p38/snail1 pathway in glioma.

Authors:  Junhui Liu; Lun Gao; Jianmin Liao; Ji'an Yang; Fan'en Yuan; Qianxue Chen
Journal:  Ann Transl Med       Date:  2021-02

6.  Prognostic value and underlying mechanism of KIAA0101 in hepatocellular carcinoma: database mining and co-expression analysis.

Authors:  Weiyu Xu; Xuezhu Wang; Xiaoqian Wu; Si Yu; Jianping Xiong; Xinting Sang; Yongchang Zheng; Zhongtao Zhang
Journal:  Aging (Albany NY)       Date:  2020-08-27       Impact factor: 5.682

7.  Low expression of PRMT5 in peripheral blood may serve as a potential independent risk factor in assessments of the risk of stable CAD and AMI.

Authors:  Buchuan Tan; Qian Liu; Liping Yang; Yushuang Yang; Dongna Liu; Long Liu; Fanbo Meng
Journal:  BMC Cardiovasc Disord       Date:  2019-01-31       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.